We continue to advance our pipeline of generic and novel diagnostic and therapeutic products, building upon our core competency in the areas of radiopharmaceuticals, lyophilized kits, and other modalities. Externally, we continually evaluate opportunities to acquire products or technologies that serve patients while strengthening our strategic position in the industry through strategic partnerships or in-licensing agreements.